Literature DB >> 21913900

Predicting the emetic liability of novel chemical entities: a comparative study.

Nathalie Percie du Sert1, Anthony M Holmes1, Rob Wallis1, Paul Lr Andrews1.   

Abstract

BACKGROUND AND
PURPOSE: Emesis is a multi-system reflex, which is usually investigated using in vivo models. The aim of the study is to compare the response induced by emetic compounds across species and investigate whether dogs, ferrets and rats are all similarly predictive of humans. EXPERIMENTAL APPROACH: A systematic review was carried out and relevant publications were identified from PubMed. The search was restricted to four species (human, dog, ferret, rat) and ten compounds representative of various mechanisms of emesis induction (apomorphine, cisplatin, cholecystokinin octapeptide, copper sulphate, cyclophosphamide, ipecacuanha, lithium chloride, morphine, nicotine, rolipram). KEY
RESULTS: 1046 publications were reviewed, and 311 were included, the main reason for exclusion was the lack of quantitative data. Emetic or pica data were extracted as incidence, intensity or latency. All three animal species identified emetic liability but interspecies differences for dose sensitivity were detected. CONCLUSIONS AND IMPLICATION: These results suggest that emetic liability can be reliably identified in a common laboratory species such as the rat. However, to evaluate the characteristics of the emetic response, no animal species is a universal predictor of emetic liability and the choice of species should be an informed decision based on the type of compound investigated. Limitations relating to the conduct and reporting of emesis studies were identified, the main ones being the lack of comparable outcome measures between human and animal data, and the limited availability of human data in the public domain.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21913900      PMCID: PMC3372835          DOI: 10.1111/j.1476-5381.2011.01669.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

1.  Guide to Receptors and Channels (GRAC), 5th edition.

Authors:  Stephen P H Alexander; Alistair Mathie; John A Peters
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

2.  Differential action of ondansetron and dexamethasone to modify cisplatin-induced acute and delayed kaolin consumption ("pica") in rats.

Authors:  John A Rudd; Kouichi Yamamoto; Atsushi Yamatodani; Noriaki Takeda
Journal:  Eur J Pharmacol       Date:  2002-11-01       Impact factor: 4.432

3.  Toxicology of ipecac: a review.

Authors:  B R Manno; J E Manno
Journal:  Clin Toxicol       Date:  1977       Impact factor: 4.467

4.  American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

Authors:  Mark G Kris; Paul J Hesketh; Mark R Somerfield; Petra Feyer; Rebecca Clark-Snow; James M Koeller; Gary R Morrow; Lawrence W Chinnery; Maurice J Chesney; Richard J Gralla; Steven M Grunberg
Journal:  J Clin Oncol       Date:  2006-05-22       Impact factor: 44.544

5.  Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference.

Authors:  F Roila; P J Hesketh; J Herrstedt
Journal:  Ann Oncol       Date:  2005-11-28       Impact factor: 32.976

Review 6.  Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research.

Authors:  Carol Kilkenny; William J Browne; Innes C Cuthill; Michael Emerson; Douglas G Altman
Journal:  PLoS Biol       Date:  2010-06-29       Impact factor: 8.029

7.  The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.

Authors:  T Gregg Davis; John J Peterson; Jen-Pyng Kou; Elizabeth A Capper-Spudich; Doug Ball; Anthony T Nials; Joanne Wiseman; Yemisi E Solanke; Fiona S Lucas; Richard A Williamson; Livia Ferrari; Paul Wren; Richard G Knowles; Mary S Barnette; Patricia L Podolin
Journal:  J Pharmacol Exp Ther       Date:  2009-06-04       Impact factor: 4.030

Review 8.  Opportunities for the replacement of animals in the study of nausea and vomiting.

Authors:  A M Holmes; J A Rudd; F D Tattersall; Q Aziz; P L R Andrews
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

Review 9.  Signals for nausea and emesis: Implications for models of upper gastrointestinal diseases.

Authors:  Paul L R Andrews; Charles C Horn
Journal:  Auton Neurosci       Date:  2006-03-23       Impact factor: 3.145

Review 10.  A review of clinical trials of lithium in medicine.

Authors:  C Y Yung
Journal:  Pharmacol Biochem Behav       Date:  1984       Impact factor: 3.533

View more
  12 in total

1.  Pioneering better science through the 3Rs: an introduction to the national centre for the replacement, refinement, and reduction of animals in research (NC3Rs).

Authors:  Natalie Burden; Kathryn Chapman; Fiona Sewell; Vicky Robinson
Journal:  J Am Assoc Lab Anim Sci       Date:  2015-03       Impact factor: 1.232

2.  Comparison of emetic potencies of the 8-ketotrichothecenes deoxynivalenol, 15-acetyldeoxynivalenol, 3-acetyldeoxynivalenol, fusarenon X, and nivalenol.

Authors:  Wenda Wu; Melissa A Bates; Steven J Bursian; Jane E Link; Brenna M Flannery; Yoshiko Sugita-Konishi; Maiko Watanabe; Haibin Zhang; James J Pestka
Journal:  Toxicol Sci       Date:  2012-09-20       Impact factor: 4.849

3.  Peptide YY3-36 and 5-hydroxytryptamine mediate emesis induction by trichothecene deoxynivalenol (vomitoxin).

Authors:  Wenda Wu; Melissa A Bates; Steven J Bursian; Brenna Flannery; Hui-Ren Zhou; Jane E Link; Haibin Zhang; James J Pestka
Journal:  Toxicol Sci       Date:  2013-03-01       Impact factor: 4.849

4.  Evaluation of chemically diverse 5-HT₂c receptor agonists on behaviours motivated by food and nicotine and on side effect profiles.

Authors:  G A Higgins; L B Silenieks; W Lau; I A M de Lannoy; D K H Lee; J Izhakova; K Coen; A D Le; P J Fletcher
Journal:  Psychopharmacology (Berl)       Date:  2012-11-25       Impact factor: 4.530

Review 5.  The role of the parasympathetic nervous system in visually induced motion sickness: systematic review and meta-analysis.

Authors:  Adam D Farmer; Yasser Al Omran; Qasim Aziz; Paul L Andrews
Journal:  Exp Brain Res       Date:  2014-05-04       Impact factor: 1.972

6.  Assessment of low-dose cisplatin as a model of nausea and emesis in beagle dogs, potential for repeated administration.

Authors:  Hannah Kenward; Ludovic Pelligand; Jonathan Elliott
Journal:  Exp Brain Res       Date:  2014-05-04       Impact factor: 1.972

7.  The multifactorial role of the 3Rs in shifting the harm-benefit analysis in animal models of disease.

Authors:  Melanie L Graham; Mark J Prescott
Journal:  Eur J Pharmacol       Date:  2015-03-28       Impact factor: 4.432

8.  Type A Trichothecene Diacetoxyscirpenol-Induced Emesis Corresponds to Secretion of Peptide YY and Serotonin in Mink.

Authors:  Qinghua Wu; Kamil Kuca; Eugenie Nepovimova; Wenda Wu
Journal:  Toxins (Basel)       Date:  2020-06-25       Impact factor: 4.546

9.  Differential hypoglycaemic, anorectic, autonomic and emetic effects of the glucagon-like peptide receptor agonist, exendin-4, in the conscious telemetered ferret.

Authors:  Zengbing Lu; Nathalie Percie Du Sert; Sze Wa Chan; Chi-Kong Yeung; Ge Lin; David T W Yew; Paul L R Andrews; John A Rudd
Journal:  J Transl Med       Date:  2014-12-10       Impact factor: 5.531

10.  Phosphodiesterase 4 inhibitor activates AMPK-SIRT6 pathway to prevent aging-related adipose deposition induced by metabolic disorder.

Authors:  Zhuoran Wang; Yaru Liang; Lu Zhang; Nannan Zhang; Qingfei Liu; Zhao Wang
Journal:  Aging (Albany NY)       Date:  2018-09-18       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.